**BCP: Board Resolution**

On June 24, 2024, ENLIE Pharmaceutical Joint Stock Company announced Resolution No. 05/2024/NQ-HDQT as follows:

‎‎Article 1. Approve updating and adjusting the dossiers for the Annual General Meeting of Shareholders 2024 as follows:

* Report on activities of the Board of Directors in 2023 and the operating orientation for 2024.
* Report of the Board of Management on the results of production and business activities in 2023 and the plan for 2024.
* Proposal No. 02: Approving the production and business plan for 2024.
* Proposal No. 03: On approving the remuneration payment of the Supervisory Board, the Secretariat of the Board of Directors of the Company in 2023 and proposing remuneration for the Board of Directors, the Supervisory Board, and the Secretariat for 2024.
* Proposal No. 05: On amending the Charter of ENLIE Pharmaceutical Joint Stock Company.
* Proposal No. 08: Approve the plan of offering private shares to increase charter capital.
* Other announced contents of the Dossier remain unchanged.

‎‎Article 2. Members of the Board of Directors, the Board of Management, and relevant departments are responsible for the implementation of this Resolution.

This Resolution takes effect from the date of its signing.